Published on 22/12/2025
The Impact of HGRAC Rules on Rare Disease Clinical Trials in China
Introduction
Rare disease clinical trials often depend on global collaboration, with sponsors seeking diverse genetic data and patient cohorts across regions. In China, the Human Genetic Resources Administration of China (HGRAC) plays a pivotal regulatory role in governing the collection, use, and export of human genetic resources, including biospecimens and genetic data. For multinational sponsors, HGRAC approval is a critical prerequisite for conducting rare disease studies in China, particularly since these trials frequently involve small patient populations and cross-border data sharing. While these regulations are designed to protect national interests and patient rights, they can pose significant operational and compliance challenges. This article examines how HGRAC requirements shape global rare disease trials, the regulatory processes involved, and strategies for sponsors to navigate this complex landscape while ensuring patient access to innovative therapies.
Background and Regulatory Framework
Origins of HGRAC Oversight
HGRAC oversight began in the late 1990s as part of China’s efforts to safeguard national genetic resources. The regulations were codified under the “Regulations on the Administration of Human Genetic Resources” (1998) and have been updated multiple times, most recently in 2019. These rules
HGRAC and NMPA Coordination
While the NMPA oversees the clinical trial framework, HGRAC specifically regulates human genetic resources used in those trials. This dual oversight means sponsors must secure both NMPA and HGRAC approvals before initiating rare disease studies involving genetic data or samples.
Case Example: Delayed Approvals
Several multinational sponsors have reported trial delays due to lengthy HGRAC review timelines, particularly when applications involved cross-border data transfer. These experiences highlight the need for early planning and close regulatory engagement.
Core Clinical Trial Insights
Approval Requirements for Rare Disease Trials
Sponsors conducting rare disease trials must submit detailed HGRAC applications that describe the study purpose, genetic resources involved, sample management, and plans for data sharing. Joint ventures with Chinese institutions are often required, ensuring local participation and oversight. Without HGRAC approval, trials cannot lawfully proceed.
Export Restrictions on Genetic Materials
HGRAC prohibits the export of Chinese human genetic resources without prior authorization. For rare disease trials that rely on global genetic analyses, this can create significant hurdles. Sponsors must either establish local laboratories in China or partner with accredited Chinese research institutions to perform testing domestically.
Data Localization and Sharing
China’s data localization laws require that genetic data generated in China remain stored on domestic servers. While anonymized or aggregated data may sometimes be shared internationally, individual-level genetic data are subject to strict controls. This creates challenges for multinational data integration, particularly in rare diseases where sample sizes are small.
Impact on Multinational Trial Design
Because of HGRAC restrictions, sponsors often need to redesign trial protocols to accommodate local testing and data analysis. This can affect timelines, costs, and harmonization with global study arms. Sponsors must also navigate additional ethics committee reviews tied to genetic data handling.
Ethical Considerations for Rare Disease Patients
Rare disease patients in China often seek access to global investigational therapies. While HGRAC oversight ensures ethical safeguards, delays in approvals can inadvertently limit patient access. Balancing national interests with urgent medical needs remains a central tension in rare disease regulation.
Role of CROs and Local Partnerships
Local CROs and academic institutions are indispensable for navigating HGRAC processes. They provide insight into evolving policies, assist with documentation, and ensure compliance with domestic laboratory and data storage requirements. Strategic partnerships are often the key to timely trial initiation.
Best Practices & Preventive Measures
Sponsors should begin HGRAC application preparation at the earliest stages of protocol development. Establishing partnerships with accredited Chinese research institutions can reduce approval risks. Sponsors should also design trial data management systems that comply with localization laws, and ensure transparency with patients and ethics committees regarding data handling. Regular communication with regulators helps mitigate delays.
Scientific & Regulatory Evidence
HGRAC regulations are informed by international principles of data protection and sovereignty. Comparisons can be drawn with the EU’s General Data Protection Regulation (GDPR) and U.S. laws on genetic privacy. However, China’s emphasis on national ownership of genetic resources distinguishes its framework. ICH E6(R2) and WHO GCP guidelines provide complementary ethical standards for rare disease trials that intersect with HGRAC oversight.
Special Considerations
Rare disease trials face unique challenges in China due to limited patient registries and diagnostic infrastructure. HGRAC requirements can exacerbate delays in trial initiation, making it essential for sponsors to collaborate with patient advocacy organizations to identify eligible patients. Pediatric rare disease trials, in particular, demand careful ethical review and parental involvement in consent processes.
When Sponsors Should Seek Regulatory Advice
Sponsors should consult HGRAC during the earliest phases of study design, especially when genetic samples or data transfer are involved. Pre-submission meetings with both HGRAC and NMPA can clarify expectations and reduce review delays. Sponsors should also seek advice when considering multi-regional rare disease trials that include China, to ensure compliance with global and domestic requirements.
Case Studies
Case Study 1: Rare Disease Trial with Delayed Sample Export
A multinational rare disease study faced a six-month delay due to HGRAC’s restrictions on exporting patient samples for overseas genomic analysis. The sponsor responded by establishing a local laboratory partnership in Beijing, which allowed the trial to proceed without further delays while ensuring compliance with localization laws.
Case Study 2: Successful Joint Venture Model
Another rare disease sponsor partnered with a Chinese academic institution to form a joint venture for data management. This collaboration streamlined HGRAC approval and improved patient recruitment by leveraging the institution’s existing rare disease registry. The trial became a model for international-local collaboration under HGRAC oversight.
FAQs
1. What is HGRAC and why is it important?
HGRAC is the Human Genetic Resources Administration of China. It regulates the collection, use, and export of human genetic resources in clinical trials.
2. Do rare disease trials always need HGRAC approval?
Yes, if genetic samples or data are involved, HGRAC approval is mandatory in addition to NMPA authorization.
3. Can genetic data from China be shared internationally?
Only under strict conditions. Individual-level data cannot leave China without authorization, and most data must remain on domestic servers.
4. How long does HGRAC approval take?
Approval timelines vary but can take several months. Early preparation and local partnerships help mitigate delays.
5. Can sponsors export patient samples from China?
Not without HGRAC authorization. In most cases, testing must be conducted within China at accredited laboratories.
6. What strategies help sponsors comply with HGRAC?
Forming joint ventures with local institutions, designing compliant data management systems, and engaging HGRAC early in protocol design are best practices.
Conclusion & Call-to-Action
HGRAC regulations significantly shape how rare disease trials are designed and conducted in China. While these rules protect national interests and patient rights, they also create challenges for multinational sponsors seeking to integrate Chinese data into global studies. By planning early, building strong local partnerships, and aligning protocols with HGRAC requirements, sponsors can overcome barriers and ensure rare disease patients in China have timely access to innovative therapies. Organizations considering rare disease trials in China should consult regulatory experts to design compliant, patient-centered strategies that support both global and domestic research goals.